title: Non-charged amino acids from three different domains contribute to link agonist binding to channel gating in alpha7 nicotinic acetylcholine receptors.
abstract: Binding of agonists to nicotinic acetylcholine receptors results in channel opening. Previously, we have shown that several charged residues at three different domains of the alpha7 nicotinic receptor are involved in coupling binding and gating, probably through a network of electrostatic interactions. This network, however, could also be integrated by other residues. To test this hypothesis, non-charged amino acids were mutated and expression levels and electrophysiological responses of mutant receptors were determined. Mutants at positions Asn47 and Gln48 (loop 2), Ile130, Trp134, and Gln140 (loop 7), and Thr264 (M2-M3 linker) showed poor or null functional responses, despite significant membrane expression. By contrast, mutants F137A and S265A exhibited a gain of function effect. In all cases, changes in dose-response relationships were small, EC(50) values being between threefold smaller and fivefold larger, arguing against large modifications of agonist binding. Peak currents decayed at the same rate in all receptors except two, excluding large effects on desensitization. Thus, the observed changes could be mostly caused by alterations of the gating characteristics. Moreover, analysis of double mutants showed an interconnection between some residues in these domains, especially Gln48 with Ile130, suggesting a potential coupling between agonist binding and channel gating through these amino acids.
authors.affiliation: Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, Sant Joan d'Alacant, Alicante, Spain.
authors.forename: Marcos
authors.initials: M
authors.lastname: Aldea
authors.forename: José
authors.initials: J
authors.lastname: Mulet
authors.forename: Salvador
authors.initials: S
authors.lastname: Sala
authors.forename: Francisco
authors.initials: F
authors.lastname: Sala
authors.forename: Manuel
authors.initials: M
authors.lastname: Criado
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D019943:Amino Acid Substitution; D000596:Amino Acids / Q000502:physiology*; D000818:Animals; D002038:Bungarotoxins / Q000378:metabolism; D002417:Cattle; D004246:Dimethylphenylpiperazinium Iodide / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004594:Electrophysiology; D015640:Ion Channel Gating / Q000235:genetics / Q000502:physiology*; D016296:Mutagenesis; D018722:Nicotinic Agonists / Q000378:metabolism*; D009865:Oocytes; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D011978:Receptors, Nicotinic / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D014982:Xenopus laevis; D064569:alpha7 Nicotinic Acetylcholine Receptor
chemical_list: D000596:Amino Acids; D002038:Bungarotoxins; D018722:Nicotinic Agonists; D012333:RNA, Messenger; D011978:Receptors, Nicotinic; D064569:alpha7 Nicotinic Acetylcholine Receptor; D004246:Dimethylphenylpiperazinium Iodide; D000109:Acetylcholine